Pricing Log in Create free account
Friday 6 November 2026 Export PACB’s income statement to Excel — free account

Pacific Biosciences of California, Inc.

PACB Healthcare Medical Devices

Pacific Biosciences of California, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $160.0 million, up 3.89% from fiscal 2024.

Revenue
+5.52%
EPS
+7.69%
Free cash flow
−102.0%
Total debt
−0.29%

Quarter to September 2026, against a year earlier

2.31 0.12 −4.94%
Market cap
$755.3M
P/E
0.0×
Fwd P/E
−5.9×
Dividend yield
—
F-score
3/9
Altman Z
−6.04
Beneish M
−5.14
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 3.37
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — 3 3 1 — — — 1 — 1 —
Insider Ownership 8.68%

Capital & Financial Ratios $m

Size
Market Cap 755.32
Revenue ttm 161.39
Net income ttm (131.23)
Free cash flow ttm (136.95)
Net debt Q (199.45)
Valuation
P/E 0.00
Forward P/E (5.85) (negative: loss-making)
Price / sales 4.74
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 4.62 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (17.99)
Growth
Revenue growth Q +5.52% (above 0%: growing)
Operating income growth Q +4.82% (above 0%: growing)
EPS, this year +74.96% (at or above 15%: strong)
EPS, next year A +1.72%
Revenue, next year A −0.82% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +41.86% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 7.5×, against a ten-year median of 7.2×; over the ten years it ranged from 1.8× in 2018 to 67.4× in 2021.
P/S against its own 10 years 34.36%
10-year low 10-year high
EV/Sales against its own 10 years 53.83%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 632 391 280 199
Receivables 37 28 35 38
Inventory 57 59 49 60
Other — — — —
742 496 375 308
2023 2024 2025 Q'26
Payables 15 17 21 11
ST’ Debt — — — —
Other 8 3 2 2
95 66 73 67

Compound Annual Growth %

10y 5y 3y
Sales 5.60% 15.19% 7.64%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (23.06%) (56.30%) (78.82%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.13 Actual −0.11

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.19 −0.12 Beat by 0.07
Q1 FY26 −0.17 −0.12 Beat by 0.05
Q2 FY26 −0.14 −0.14 Met by 0.00
Q3 FY26 −0.13 −0.11 Beat by 0.02
Q4 FY26 −0.13 — Reports 11 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.03) (0.14) (0.12) — —
’25 (1.44) (0.14) (0.13) (0.13) (1.82)
’24 (0.29) (0.64) (0.22) (0.49) (1.59)
’23 (0.36) (0.28) (0.26) (0.31) (1.21)
’22 (0.37) (0.32) (0.34) (0.37) (1.40)
’21 (0.45) (0.21) 0.08 (0.31) (0.89)
’20 0.01 (0.15) (0.14) 0.37 0.17
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 37 39 41 — —
’25 37 40 38 45 160
’24 39 36 40 39 154
’23 39 48 56 58 201
’22 33 35 32 27 128
’21 29 31 35 36 131
’20 16 17 19 27 79
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (45) (36) (38) — —
’25 (44) (29) (19) (19) (111)
’24 (76) (54) (45) (31) (206)
’23 (95) (42) (65) (58) (259)
’22 (79) (61) (63) (61) (263)
’21 (23) (16) (41) (32) (111)
’20 75 (24) (18) (14) 20
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (39) (38) — —
’25 (50) (30) (19) (20) (119)
’24 (80) (56) (45) (32) (212)
’23 (98) (44) (66) (60) (268)
’22 (83) (65) (67) (66) (280)
’21 (24) (17) (42) (35) (117)
’20 75 (24) (18) (14) 18
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 91 93 79 91 79 131 128 201 154 160 161 +6.5% 159 184 211 +9.7%
Gross margin, % 48.68 37.08 31.92 38.04 41.28 45.10 38.22 26.32 24.21 28.61 34.40 (20.1) pt
EBT (74) (92) (103) (84) 29 (275) (314) (318) (310) (546) (131) +24.8%
EBT margin, % (81.99) (98.63) (130.44) (92.57) 37.27 (210.61) (244.92) (158.67) (200.98) (341.28) (80.87) (259.3) pt
Net income (74) (92) (103) (84) 29 (181) (314) (307) (310) (546) (131) +24.8%
Per share, $
Per share, $ Revenue 1.02 0.88 0.58 0.60 0.48 0.64 0.57 0.79 0.56 0.53 0.52 (6.9%)
Earnings (0.83) (0.87) (0.76) (0.55) 0.18 (0.89) (1.40) (1.21) (1.12) (1.82) (0.42) +9.1%
Cash flow (0.76) (0.64) (0.49) (0.51) 0.12 (0.54) (1.17) (1.02) (0.75) (0.37) (0.44) (7.7%)
Capex (0.09) (0.10) (0.01) (0.02) (0.01) (0.03) (0.08) (0.03) (0.02) (0.03) 0.00 (13.2%)
Free cash flow (0.85) (0.74) (0.51) (0.53) 0.11 (0.57) (1.25) (1.06) (0.77) (0.40) (0.44) (8.2%)
Book value 0.95 0.81 0.84 0.36 2.03 3.87 2.51 2.77 1.85 0.02 (0.20) (35.7%)
Shares, m 89 106 135 153 165 204 225 254 274 300 307 +14.4%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 216.17 0.00 0.00 0.00 0.00 0.00 0.00 21.6
P/S 4.28 3.15 12.71 8.63 54.31 32.00 13.90 12.13 3.26 3.51 4.74 14.8
P/B 4.59 3.42 8.76 14.28 12.77 5.28 3.17 3.47 0.99 104.86 0.00 16.2
EV/Sales 3.67 2.63 11.60 8.54 50.74 30.86 14.86 13.43 4.93 5.79 7.50 14.7
EV/FCF (4.37) (3.15) (13.36) (9.57) 216.82 (34.39) (6.81) (10.05) (3.58) (7.79) (12.18) 12.4
Cash, $m
Cash, $m Operating cash flow (68) (68) (66) (78) 20 (111) (263) (259) (206) (111) (137) +5.6%
Capex (8) (10) (2) (3) (1) (6) (17) (9) (6) (8) 38 (0.7%)
Free cash flow (76) (78) (68) (81) 18 (117) (280) (268) (212) (119) (137) +5.1%
Balance, $m
Balance, $m Working capital 75 73 105 32 317 1,029 589 647 429 302 241 +16.7%
Net debt (56) (49) (88) (7) (282) (149) 124 261 257 366 (199) n/m
Shareholders’ equity 85 86 114 55 335 791 563 701 507 5 (61) (26.4%)
Returns, %
Returns, % ROA (55.30) (65.39) (65.25) (52.87) 10.46 (14.97) (16.65) (17.46) (20.61) (53.45) (17.22) +1.9 pt
ROIC (154.63) (152.21) (239.39) (132.25) (121.17) (20.48) (27.95) (21.73) (38.83) (93.25) 0.00 +61.4 pt
ROE (94.02) (107.97) (102.48) (99.58) 15.06 (32.18) (46.42) (48.53) (51.30) (213.45) 1,037.83 (119.4) pt
People
People Employees 438 456 401 404 412 728 769 796 575 485 — +1.1%
Revenue/emp, $m 0.21 0.20 0.20 0.22 0.19 0.18 0.17 0.25 0.27 0.33 — +5.3%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Pacific Biosciences of California, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AHCO AdaptHealth Corp. $1.0B — (loss-making) — (loss-making) +10.90% (above 0%: growing) n/m −23.58% (below 0%: shrinking) 15.40% (20.91%) Compare
BVS Bioventus Inc. $899.9M 12.3× 17.2× +2.73% (above 0%: growing) +100.60% (above 0%: growing) −31.40% (below 0%: shrinking) 68.19% 6.81% Compare
QDEL QuidelOrtho Corporation $880.5M — (loss-making) — (loss-making) −11.57% (below 0%: shrinking) n/m +120.70% (above 0%: growing) 46.79% (1.21%) Compare
BBNX Beta Bionics, Inc. $842.1M — (loss-making) — (loss-making) +30.28% (above 0%: growing) n/m −45.46% (below 0%: shrinking) 57.26% (74.94%) Compare
KIDS OrthoPediatrics Corp. $841.3M — (loss-making) — (loss-making) +18.63% (above 0%: growing) n/m +146.64% (above 0%: growing) 74.28% (5.81%) Compare
VREX VAREX IMAGING $783.0M 34.8× 39.2× +3.69% (above 0%: growing) n/m +757.14% (above 0%: growing) 36.44% 10.83% Compare
INMD InMode Ltd. $771.1M 10.7× 11.8× −0.01% (below 0%: shrinking) −30.95% (below 0%: shrinking) −12.63% (below 0%: shrinking) 74.82% 12.82% Compare
PACB Pacific Biosciences of California, Inc. $755.3M — (loss-making) — (loss-making) +5.52% (above 0%: growing) n/m −101.95% (below 0%: shrinking) 33.21% (91.22%)
CTKB Cytek Biosciences, Inc. $701.9M — (loss-making) — (loss-making) +1.79% (above 0%: growing) n/m −30.25% (below 0%: shrinking) 58.63% (15.82%) Compare
Median of peers $841.7M 12.3× 17.2× +3.21% — −18.10% 57.95% (3.51%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 23 April 2026

Ownership

Directors and executive officers, together 3.70%
ARK Investment Management LLC 12.00%
BlackRock, Inc. 7.40%
SB Northstar LP 6.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Pacific Biosciences of California, Inc. (PACB) Latest News

5 Nov

Impact 3 · · GuruFocus.com

4 Nov

Impact 3 · · MarketBeat transcript
Impact 3 · · Associated Press
Impact 3 · · GlobeNewswire

29 Oct

Impact 3 · · Zacks

27 Oct

Impact 4 · · Zacks
Impact 3 · · GlobeNewswire
Impact 3 · · StockStory

22 Oct

Impact 3 · · Zacks

19 Oct

Impact 4 · · GlobeNewswire

14 Oct

Impact 3 · · Zacks

13 Oct

Impact 4 · · Zacks

8 Oct

Impact 3 · · Simply Wall St.
Impact 3 · · Zacks

6 Oct

Impact 4 · · GlobeNewswire
Impact 3 · · TIKR

5 Oct

Impact 3 · · StockStory

2 Oct

Impact 3 · · Zacks

30 Sep

Impact 4 · · StockStory

25 Sep

Impact 3 · · Zacks

24 Sep

Impact 3 · · StockStory

20 Sep

Impact 4 · · MarketBeat

8 Sep

Impact 3 ·

2 Sep

Impact 4 ·

16 Aug

Impact 4 · · MarketBeat

14 Aug

Impact 3 ·

6 Aug

Impact 4 ·
Impact 4 · · MarketBeat transcript

5 Aug

Impact 3 ·
Impact 3 ·
stockrow.com/PACB · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com